Dihydropyridine calcium channel blockers and renal disease

Nicolás R. Robles, Francesco Fici, Guido Grassi

Research output: Contribution to journalReview articlepeer-review


Although blood pressure control is considered the main mechanism for preventing the progression of chronic kidney disease (CKD), angiotensin-converting enzyme inhibitors and angiotensin receptors blockers have an additional organ-protective role. The effects of calcium channel blockers (CCBs) in renal disease are not so clearly defined. CCBs have pleiotropic effects that might contribute to protection of the kidney, such as attenuating the mesangial entrapment of macromolecules, countervailing the mitogenic effect of platelet-derived growth factors and platelet-activating factors and suppressing mesangial cell proliferation. Some evidence has accumulated in recent years demonstrating that the new dihydropyridinic CCBs (such as lercanidipine or efonidipine) may affect both postglomerular and preglomerular vessels, resulting in a decreased filtration fraction and nephroprotective effect. Increasing clinical and experimental evidence supports this view and the use of CCBs in CKD hypertensive patients.

Original languageEnglish
Pages (from-to)21-28
Number of pages8
JournalHypertension Research
Issue number1
Publication statusPublished - Jan 1 2017


  • Calcium channel blockers
  • Chronic kidney disease
  • Renal failure

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Dihydropyridine calcium channel blockers and renal disease'. Together they form a unique fingerprint.

Cite this